To investigate the hypothesis that rare germline ERBB2 variants predispose to multiple types of hematologic neoplasms, targeted sequencing of ERBB2 was analyzed in a cohort of 1604 consecutive individuals who underwent clinical evaluation for hematologic malignancy over a 5-year period from 2015 to 2020. This evidence concerns the gene ERBB2 and hematologic disorder.